EREG and posterior cortical atrophy: When the EREG-specific monoclonal antibody (EREG mAb) was used, a markedly reduced viability of PCa cells was observed, with the effect comparable to or even higher than that of either AG-1478 or cetuximab, the latter a Food and Drug Administration (FDA)-approved EGFR-targeting monoclonal antibody (Fig. 4g).